ADVFN
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
Revive Therapeutics Ltd

Revive Therapeutics Ltd (RVV)

0.02
0.00
(0.00%)
Closed July 20 4:00PM

Revive Therapeutics Ltd (RVV) Quote

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
0.02
( - )
Bid
0.015
Ask
0.02
Volume
774,250
0.015 Day's Range 0.02
0.005 52 Week Range 0.035
Previous Close
0.02
Open
0.02
Last Trade
50000
@
0.02
Last Trade Time
Average Volume (3m)
253,896
Financial Volume
-
VWAP
-

RVV Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.00533.33333333330.0150.020.0153545770.02CS
4000.020.0250.0152519910.02020067CS
12-0.01-33.33333333330.030.0350.0152538960.02341519CS
260.011000.010.0350.0052965240.01832388CS
520.00533.33333333330.0150.0350.0053188780.01402612CS
156-0.465-95.87628865980.4850.4850.0053187930.06778647CS
260-0.195-90.69767441860.2150.920.0057083130.33222607CS

RVV - Frequently Asked Questions (FAQ)

What is the current Revive Therapeutics share price?
The current share price of Revive Therapeutics is $ 0.02
What is the 1 year trading range for Revive Therapeutics share price?
Revive Therapeutics has traded in the range of $ 0.005 to $ 0.035 during the past year

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SPFYSpacefy Inc
$ 0.02
(100.00%)
28.37k
CSSCascada Silver Corp
$ 0.01
(100.00%)
105.64k
VOLTVoltage Metals Corp
$ 0.01
(100.00%)
5k
GGCGeneric Gold Corp
$ 0.145
(93.33%)
197.73k
QBTQSuperQ Quantum Computing Inc
$ 1.20
(60.00%)
196.99k
LTHMChampion Electric Metals Inc
$ 0.005
(-50.00%)
182k
PUMPStock Trend Capital Inc
$ 0.005
(-50.00%)
127.99k
MBIOMindBio Therapeutics Corp
$ 0.005
(-50.00%)
13k
CMTCullinan Metals Corp
$ 0.01
(-50.00%)
25k
SURESureNano Science Ltd
$ 0.12
(-33.33%)
25k
WHIPCredissential Inc
$ 0.015
(0.00%)
11.99M
HGHydrograph Clean Power Inc
$ 0.35
(18.64%)
6.48M
AUOZEmperor Metals Inc
$ 0.30
(33.33%)
3.36M
PXIPlanet Ventures Inc
$ 0.34
(36.00%)
3.31M
QIMCQuebec Innovative Materials Corp
$ 0.185
(12.12%)
2.1M

RVV Discussion

View Posts
ReikoBlack ReikoBlack 2 weeks ago
The previous Press Release stated that, "...the research study on Bucillamine is now set to conclude by September 2025."

The recent Press Release states, "The research study with Bucillamine is slated for continuation through September 2025."

It sounds like the study will not be concluded in September as originally stated. Goal posts continue to be moved.



News Out, Study Update.....huh 😳


https://www.globenewswire.com/news-release/2025/07/08/3112245/0/en/Revive-Therapeutics-Clarifies-Completion-of-Key-Nerve-Agent-Countermeasure-Study.html

Did MF say something he shouldn't have in the previous Press Release??? Is this a damage control Press Release??
👍️0
Milesblue42 Milesblue42 2 weeks ago
NO Pump: Bucillamine + Molecular hydrogen = ????


DISCLAIMER: This post is not designed to try and pump this stock but merely a question. Could a combination of Bucillamine and Molecular hydrogen actually have real medical benefits? Benefits that could possibly significantly impact the share price? Or is this merely an elaborate time buying tactic that will amount to nothing at all?

https://www.globenewswire.com/news-release/2025/03/03/3035573/0/en/Revive-Therapeutics-Announces-LOI-to-Acquire-DiagnaMed-s-Molecular-Hydrogen-Program.html
Revive Therapeutics Announces LOI to Acquire DiagnaMed’s Molecular Hydrogen Program

March 03, 2025 08:00 ET | Source: Revive Therapeutics Ltd.

Share

TORONTO, March 03, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, rare disorders, and medical countermeasures, is pleased to announce that it has entered into a non-binding letter of intent (the “LOI”), dated February 28, 2025, to acquire the full rights to DiagnaMed Holdings Corp.’s (CSE: DMED) (OTCQB: DGNMF) (“DiagnaMed”) intellectual property (the “Acquired Assets”) pertaining to molecular hydrogen as potential treatments for neurological and mental health disorders (the “Acquisition”).


Molecular hydrogen, a small molecule with antioxidant and anti-inflammatory properties, has shown early promise in preclinical studies for its ability to mitigate oxidative stress and inflammation—key factors implicated in ALS progression. The FDA’s decision paves the way for Revive to accelerate its development programs with molecular hydrogen.



The National Center for Biotechnology Information article on Molecular hydrogen

https://pmc.ncbi.nlm.nih.gov/articles/PMC8861563/

Molecular hydrogen is a promising therapeutic agent for pulmonary disease
Zhiling FU 1, Jin ZHANG 1,✉

PMCID: PMC8861563 PMID: 35187885
Abstract

Molecular hydrogen exerts biological effects on nearly all organs. It has anti-oxidative, anti-inflammatory, and anti-aging effects and contributes to the regulation of autophagy and cell death. As the primary organ for gas exchange, the lungs are constantly exposed to various harmful environmental irritants. Short- or long-term exposure to these harmful substances often results in lung injury, causing respiratory and lung diseases. Acute and chronic respiratory diseases have high rates of morbidity and mortality and have become a major public health concern worldwide. For example, coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global pandemic. An increasing number of studies have revealed that hydrogen may protect the lungs from diverse diseases, including acute lung injury, chronic obstructive pulmonary disease, asthma, lung cancer, pulmonary arterial hypertension, and pulmonary fibrosis. In this review, we highlight the multiple functions of hydrogen and the mechanisms underlying its protective effects in various lung diseases, with a focus on its roles in disease pathogenesis and clinical significance.



Is the DiagnaMed acquisition by Revive Therapeutics the reason for being contacted by a prominent clinical researcher from a U.S. University Cancer Institute? Is there really or could there be something there by using Bucillamine and Molecular Hydrogen to treat solid tumors?? Or is this smoke and mirrors designed to time?

https://www.globenewswire.com/news-release/2025/04/10/3059109/0/en/Revive-Therapeutics-to-Investigate-Bucillamine-s-Potential-in-Cancer-Treatment.html

Revive Therapeutics to Investigate Bucillamine’s Potential in Cancer Treatment

April 10, 2025 07:00 ET | Source: Revive Therapeutics Ltd.



TORONTO, April 10, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, rare disorders, and medical countermeasures, announced today that it has been contacted by a prominent clinical researcher from a U.S. University Cancer Institute. The researcher aims to investigate Bucillamine’s potential as a cancer treatment, particularly for boosting anti-tumor effects in patients with advanced solid tumors. This evaluation of Bucillamine in solid tumors would be integrated into a broader study, supported by funding from the NIH and/or other government entities. This proposed research builds on our strategy of evaluating novel uses of Bucillamine in academic and government supporting studies, including the partnership with Defence R&D Canada – Suffield Research Centre, an agency of the Canadian Department of National Defence, evaluating Bucillamine as a potential treatment for nerve agent exposure. Results from this study are expected shortly.]

*****The share price at the time of this post. Could it one day go significantly higher......or significantly lower? We'll see.....******

👍️0
Nosnibor Nosnibor 2 weeks ago
Finally some encouraging news. To buy or not to buy (more shares)..
👍️0
Milesblue42 Milesblue42 2 weeks ago
News Out, Study Update.....huh 😳


https://www.globenewswire.com/news-release/2025/07/08/3112245/0/en/Revive-Therapeutics-Clarifies-Completion-of-Key-Nerve-Agent-Countermeasure-Study.html

Did MF say something he shouldn't have in the previous Press Release??? Is this a damage control Press Release??
👍️0
Nosnibor Nosnibor 2 weeks ago
Ok thanks mate.
👍️0
hotmeat hotmeat 2 weeks ago
If Buccy is successful that would be excellent but the attention I pay to this stock is very limited.
👍 1
hotmeat hotmeat 2 weeks ago
I was speculating that the Canadian govt, through their version of the DOD, was funding RVV because there hasn't been any dilution for quite some time now.

Unless MF has secured, or set aside funds to carry out these Buccy trials I don't see where else the $$ could be coming from.

You haven't missed much in terms of progress....its basically been the usual vague Prs from the company that gives little to no details to get excited about.

I'm peruse the board periodically, like most I'm sure, patiently waiting for Mike to finally accomplish something tangible.
👍️ 1
Nosnibor Nosnibor 2 weeks ago
Can you please elaborate on the "Can govt has been funding operations.."? I hold a ton of RVVTF shares but admittedly am well behind on what's happening. Thanks for posting and sounds encouraging. 
👍️0
Milesblue42 Milesblue42 2 weeks ago
Thanks for the feedback! 👍️

The AS has been that ridiculous amount (999 bil) for quite some time now and the same goes for the OS, so at least the company hasn't been diluting to pay its bills.

It does appear that the Can govt has been funding operations so that's a +Ve but as far as Revive's future, its all dependent on the success of the trials.

If the trials are somehow successful especially the Cancer Trial, is it crazy to think this could go past 50 cents??
👍️0
hotmeat hotmeat 2 weeks ago
The AS has been that ridiculous amount (999 bil) for quite some time now and the same goes for the OS, so at least the company hasn't been diluting to pay its bills.

It does appear that the Can govt has been funding operations so that's a +Ve but as far as Revive's future, its all dependent on the success of the trials.
👍️0
Milesblue42 Milesblue42 2 weeks ago
AS Increase....Good or Bad sign???

The number of Authorized shares have increased? Bad sign???

https://www.otcmarkets.com/stock/RVVTF/security
👍️0
hotmeat hotmeat 2 weeks ago
At this point there's simply too many IF's and no real concreted developments.

If this potential fast tracking by the Can government occurs, only then will I give Revive any serious consideration.

There has been simply too many "misfires" from this Ceo to have any confidence in anything he puts out IMO.
👍️ 1
Milesblue42 Milesblue42 3 weeks ago
Something I found to be interesting...

I see no mention of Human trials in this PR. Is this study being pushed back because possible new laws will allow faster approvals?? Also regarding the mention of stockpiling, does this mean that the Canadian Government might place an order before year's end if this whole thing is actually real??

https://www.gurufocus.com/news/2947354/revive-therapeutics-rvvtf-advances-bucillamine-study-for-nerve-agent-exposure-rvvtf-stock-news


Ongoing promirsing results from the study and current regulatory efforts indicate there could be pathways for Health Canada to expedite approval processes. This fast-tracked approval would support strategic plans for stockpiling treatments against nerve agent or organophosphate pesticide poisoning by 2026. Additionally, there are plans to investigate Bucillamine's potential application in treating traumatic brain injuries from explosive forces and viral infections.
👍️0
Classic Warrior Classic Warrior 3 weeks ago
Unfortunately, my response to your post has been delayed for three months like our trial.
🤪 1
hotmeat hotmeat 3 weeks ago
Its the typical release we have come to expect from Revive in that it lacks any concrete details and as such its effect on the PPS was predictably non existent.
👍️0
Milesblue42 Milesblue42 3 weeks ago
NEWS OUT

https://www.gurufocus.com/news/2947354/revive-therapeutics-rvvtf-advances-bucillamine-study-for-nerve-agent-exposure-rvvtf-stock-news

Another delay or something very promising??
👎️ 1
Classic Warrior Classic Warrior 4 weeks ago
There is no lettuce, ketchup, onions or bun unfortunately. The saga continues.
👍️0
Milesblue42 Milesblue42 1 month ago
A Nothing Burger or Something Big??


https://www.fda.gov/news-events/press-announcements/fda-issue-new-commissioners-national-priority-vouchers-companies-supporting-us-national-interests

How might this apply if at all to RVVTF?? 😳
👍️ 1
Gatorca Gatorca 1 month ago
Oh chit great dd lol 😆 really hope it does get used because i know it can be a great for many things but got a gready ass ceo rather have his 3ok a month than help people with it
Ps. Maybe this 1 won't get deleted lol
Ps2 my 401k ok even though tariffs lol

Well.ps5 time to play with my daughter
👍️0
Gatorca Gatorca 1 month ago
Must be the vodka lol ops:;) but Bucillamine os probably good many thing's but scam Mf lol 😆
👍️0
Gatorca Gatorca 1 month ago
Probably get deleted Lol 😆 don't give a .fuge
👍️0
threebabiesbusy threebabiesbusy 1 month ago
POSTED WHAT I FOUND. HOPE YOU ARE DOING WELL CW!
👍️ 1 😅 2
threebabiesbusy threebabiesbusy 1 month ago
https://www.biospace.com/press-releases/revive-therapeutics-advances-with-next-generation-bucillamine-development

Revive Therapeutics Advances with Next-Generation Bucillamine Development
June 4, 2025 | 4 min read

TORONTO, June 04, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, is pleased to announce the advancement of its next-generation lyophilized formulation of Bucillamine (“New Bucillamine”). Developed in collaboration with the esteemed University of Waterloo, this breakthrough aims to address significant unmet medical needs and unlock substantial value for shareholders.

Strategic Development Targeting High-Value Opportunities

Revive is strategically positioning New Bucillamine to target public health emergencies such as pandemic influenza and emerging infectious diseases. Additionally, the company will pursue FDA incentives, including Emergency Use Authorization, Orphan Drug Designation, Fast Track, and Breakthrough Therapy designations, maximizing the potential for rapid market entry and revenue generation.

Highlighting its potential, Bucillamine, a potent antioxidant and anti-inflammatory, already boasts FDA Orphan Drug Designation for ischemia-reperfusion injury following solid organ transplantation. This designation, awarded in 2022, underscores the compound's promise and provides a pathway to accelerated development and commercialization. Furthermore, research suggests Bucillamine may enhance solid tumor treatments in cancer and the Company has been contacted by a prominent clinical researcher from a U.S. University Cancer Institute to investigate Bucillamine for boosting anti-tumor effects in patients with advanced solid tumors, potentially opening up another significant market segment.

Strong Partnerships and Ongoing Research Driving Growth

Revive is committed to fostering strong pharmaceutical and government collaborations to accelerate New Bucillamine's clinical and commercial development. Currently, the company is working with Defence R&D Canada – Suffield Research Centre (DRDC), part of the Canadian Department of National Defence, on a study evaluating Bucillamine for nerve agent exposure. Positive results, expected by June 2025, could pave the way for human clinical trials in the second half of 2025 and subsequent FDA and Health Canada approvals. The potential applications of Bucillamine extend to traumatic brain injury and viral infections, further expanding its market potential and long-term value for investors.

Revive also reports that it is continuing to work with LTS Lohmann Therapie-System AG to settle the previously announced arbitration award.

About Revive Therapeutics Ltd.

Revive Therapeutics is a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs. Revive strategically prioritizes its drug development pipeline to leverage FDA regulatory incentives like Emergency Use Authorization, Orphan Drug, Fast Track, and Breakthrough Therapy designations, positioning for rapid advancement and market entry. Currently, our efforts are concentrated on unlocking the vast potential of Bucillamine for infectious diseases and medical countermeasures, including the pioneering treatment of nerve agent exposure. Furthermore, Revive is vigorously advancing our Psilocybin and molecular hydrogen therapeutic programs, exploring new frontiers in medical science. For more information, visit www.ReviveThera.com.

For more information, please contact:

Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: 1 888 901 0036
Email: mfrank@revivethera.com
Website: www.revivethera.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider has reviewed or accepts responsibility for the adequacy or accuracy of this release.
👍️ 1
threebabiesbusy threebabiesbusy 1 month ago
Revive Therapeutics Advances Next-Gen Bucillamine for Critical Medical Needs
TipRanks Canadian Auto-Generated Newsdesk
Jun 04, 2025, 06:42 AM

Story Highlights
Revive Therapeutics is advancing its next-gen Bucillamine for public health emergencies.
Bucillamine’s potential spans cancer treatment, nerve agent exposure, and viral infections.
Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Revive Therapeutics Advances Next-Gen Bucillamine for Critical Medical Needs

Add TSE:RVV to your watchlist
and never miss an update about TSE:RVV stock!

Revive Therapeutics ( RVV +20.00% ? ) has issued an update.

Revive Therapeutics Ltd. has announced the advancement of its next-generation lyophilized formulation of Bucillamine, developed in collaboration with the University of Waterloo. This new formulation targets public health emergencies and aims to leverage FDA incentives for rapid market entry. Bucillamine already holds FDA Orphan Drug Designation for ischemia-reperfusion injury and has potential applications in cancer treatment, nerve agent exposure, traumatic brain injury, and viral infections. The company is working with Defence R&D Canada on a study for nerve agent exposure, with positive results potentially leading to human trials and regulatory approvals. These developments could significantly expand Bucillamine’s market potential and long-term value for investors.


Spark’s Take on TSE:RVV Stock


According to Spark, TipRanks’ AI Analyst, TSE:RVV is a Neutral.


The overall stock score for Revive Therapeutics is primarily influenced by significant financial challenges, such as no revenue and ongoing losses. Despite this, the company demonstrates short-term bullish technical indicators and has made strategic moves to expand its pipeline through recent acquisitions and collaborations. However, the negative P/E ratio and lack of profitability remain concerns.


To see Spark’s full report on TSE:RVV stock, click here.


More about Revive Therapeutics


Revive Therapeutics Ltd. is a specialty life sciences company focused on developing innovative therapeutics for critical medical needs. The company strategically prioritizes its drug development pipeline to leverage FDA regulatory incentives, aiming for rapid advancement and market entry. Revive’s efforts are concentrated on the potential of Bucillamine for infectious diseases and medical countermeasures, as well as advancing its Psilocybin and molecular hydrogen therapeutic programs.


Average Trading Volume: 257,272


Technical Sentiment Signal: Sell


Current Market Cap: C$12.56M




See more data about RVV stock on TipRanks’ Stock Analysis page.



Trending Articles:
Comcast Stock (NASDAQ:CMCSA) Gains With a New Sports Connection
“Lackluster” WWDC Ahead: Apple Stock (NASDAQ:AAPL) Gains as Strategy Questioned
“A Good Entry Point”; Tesla Stock (NASDAQ:TSLA) Jumps as Fundstrat Sees an Opportunity

Disclaimer & Disclosure


Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.


Report an Issue


Revive Therapeutics (TSE:RVV) Technical Sentiment
1 Day
3 Days
1 Week
2 Weeks
1 Month
Overall Consensus
Technical Analysis Consensus
Moving Averages Consensus
Unlock Full Indicators
Related Articles
Revive Therapeutics Advances Bucillamine Research for Nerve Agent Exposure
Revive Therapeutics Announces Shares for Debt Transaction to Preserve Cash
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Latest News Feed
Paramount Stock (NASDAQ:PARA) Notches Up Despite Internal Tragedy
56m ago
PARA
Deutsche Bank (DB) Considers Launching Its Own Stablecoin
57m ago
DB
Ford Stock (NYSE:F) Gains with Better Access to Rare Earths
1h ago
F
GM
U.S. Layoffs Surge despite Strong Jobs Data as Major Corporations Make Cuts
2h ago
👍️ 1
threebabiesbusy threebabiesbusy 1 month ago
https://www.stocktitan.net/news/RVVTF/revive-therapeutics-advances-with-next-generation-bucillamine-hz634mnp5ipj.html

Revive Therapeutics (RVVTF) announces advancement in developing a next-generation lyophilized formulation of Bucillamine in collaboration with the University of Waterloo. The company is positioning New Bucillamine to target public health emergencies, including pandemic influenza and emerging infectious diseases. Bucillamine, which already holds FDA Orphan Drug Designation for ischemia-reperfusion injury in organ transplantation since 2022, shows promise in enhancing solid tumor treatments. The company is working with Defence R&D Canada to evaluate Bucillamine for nerve agent exposure, with results expected by June 2025. Clinical trials could begin in H2 2025, pending positive results. Revive is pursuing various FDA incentives and exploring partnerships to accelerate development and commercialization.

06/04/2025 - 05:55 AM
TORONTO, June 04, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, is pleased to announce the advancement of its next-generation lyophilized formulation of Bucillamine (“New Bucillamine”). Developed in collaboration with the esteemed University of Waterloo, this breakthrough aims to address significant unmet medical needs and unlock substantial value for shareholders.

Strategic Development Targeting High-Value Opportunities

Revive is strategically positioning New Bucillamine to target public health emergencies such as pandemic influenza and emerging infectious diseases. Additionally, the company will pursue FDA incentives, including Emergency Use Authorization, Orphan Drug Designation, Fast Track, and Breakthrough Therapy designations, maximizing the potential for rapid market entry and revenue generation.

Highlighting its potential, Bucillamine, a potent antioxidant and anti-inflammatory, already boasts FDA Orphan Drug Designation for ischemia-reperfusion injury following solid organ transplantation. This designation, awarded in 2022, underscores the compound's promise and provides a pathway to accelerated development and commercialization. Furthermore, research suggests Bucillamine may enhance solid tumor treatments in cancer and the Company has been contacted by a prominent clinical researcher from a U.S. University Cancer Institute to investigate Bucillamine for boosting anti-tumor effects in patients with advanced solid tumors, potentially opening up another significant market segment.

Positive
FDA Orphan Drug Designation already secured for ischemia-reperfusion injury application
Potential expansion into multiple high-value markets including cancer treatment and nerve agent exposure
Ongoing collaboration with Defence R&D Canada with results expected June 2025
Strategic pursuit of multiple FDA incentives including Emergency Use Authorization and Fast Track designation

Negative
Pending arbitration settlement with LTS Lohmann Therapie-System AG
Clinical trials for nerve agent exposure application not yet started
No immediate revenue generation from current developments

GLTA!
3BB
👍️ 1
Classic Warrior Classic Warrior 1 month ago
I find it more troubling that none of my boys posted the news release from yesterday.
👍️ 1
threebabiesbusy threebabiesbusy 1 month ago
Pittiful volume.
👍️0
threebabiesbusy threebabiesbusy 1 month ago
Pittiful volume.
👍️0
Ecomike Ecomike 2 months ago
He has a whole bag of Jimerish tricks, but the bag is super tiny LOL
👍️0
jimr1717 jimr1717 2 months ago
Someone put a couple of nickels together and bought this pos.
👍️0
bodyshop13 bodyshop13 2 months ago
It would be great if you had two nickels to rub together. Broke *ic*
👍️ 1
Classic Warrior Classic Warrior 2 months ago
That's clever how you rhymed pumping with dumping. Can you also balance a ball on your nose?
👍️ 2 😍 2 🤣 3
jimr1717 jimr1717 2 months ago
If EGOmike ©.is pumping you better be dumping
👍 1
threebabiesbusy threebabiesbusy 2 months ago
Ditto!!
👍️ 1
threebabiesbusy threebabiesbusy 2 months ago
Ditto!
👍️0
Ecomike Ecomike 2 months ago
My only regret is not loading the boat with more shares at the bottom.

Track Record? $RVVTF is still here, and so am I.

The CEO??? Even a blind Squirrel gets lucky and finds a nut some times. Still current, listed in three countries/markets and expanding the opportunities and uses for Bucillamine.



👍️ 2 😂 2
tripmcneely tripmcneely 2 months ago
Knowing MF's track record what do you think?
👍️0
Milesblue42 Milesblue42 2 months ago
Real Update....or MF Time Buying??

Is today's MF Press Release an actual real update? Or simply a time buying move by MF?
👍️0
lolroflmao lolroflmao 2 months ago
News: Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
https://finance.yahoo.com/news/revive-therapeutics-provides-research-study-180700649.html
👍️ 1 💯 1
ReikoBlack ReikoBlack 3 months ago
"In light of feedback from shareholders, the Board of Directors decided not to proceed with the proposal to amend of the Company’s articles of incorporation to consolidate its outstanding Common Shares."
https://finance.yahoo.com/news/revive-therapeutics-announces-results-annual-131400103.html


RVVTF voted to not do a R/S about 8 weeks ago
👍️ 1
Ecomike Ecomike 3 months ago
RVVTF voted to not do a R/S about 8 weeks ago
👍️0
PennyWorld PennyWorld 3 months ago
govps.... so what happened to the reverse split?
👍️0
Milesblue42 Milesblue42 3 months ago
Possibly News in May 2025???

News this month or following months??

Is it possible that MF actually comes through??
👍️0
Gatorca Gatorca 3 months ago
Hope it works out Cw
Ps. at this point would need to
take money out of 401 k.
Still would like to see bucillamine used for Something LOL.....
👍️ 1
threebabiesbusy threebabiesbusy 3 months ago
Hi Mike! Weighing option of buying more. I've been trying to keep up with the news. Agree with you about cancer being a reasonable direction to focus on.
Stay in touch!!
👍️ 1
threebabiesbusy threebabiesbusy 3 months ago
Thanks HM...Keeping a close eye on it...
👍️0
Classic Warrior Classic Warrior 3 months ago
One can only hope this goes up as quickly as it went down. We haven't seen any good trial news in years, just lots of letters of intent, etc. Hopefully, the trial news come out at some point, backing the relevance and anti-inflammatory nature of Bucy, $.15 with good news and support from Canada doesn't seem out of the question. .
👍️ 3
Milesblue42 Milesblue42 3 months ago
Could this hit 15 cents?

Realistically, if MF actually comes through what price could be seen??
👍️0
hotmeat hotmeat 3 months ago
Put in a GTC order a few days back but nothing yet.

Doesn't appear there will be any more sub 02s buying opportunities anytime soon.
👍️0
hotmeat hotmeat 3 months ago
The recent spike appears to be due to the shares for debt arrangement @ $0.025 recently announced.

Nothing tangible on the clinical side as of yet but its advisable to keep watch on this one as the PPS could see further increases.
👍️0

Your Recent History

Delayed Upgrade Clock